Rogerio C. Lilenbaum, MD

Professor of Medicine (Medical Oncology); Chief Medical Officer of Smilow Cancer Hospital

Physician Biography

Dr. Lilenbaum received his medical degree from the Federal University of Rio de Janeiro School of Medicine in Brazil and earned a masters degree in clinical epidemiology and clinical investigation from the Harvard School of Public Health. He completed his hematology/oncology fellowship at Washington University School of Medicine and a clinical and research fellowship at the University of California San Diego.

Patient Care

Accepts new patients? Yes
Patient Type: Adult
Referrals: From patients or physicians

Patient Care Organizations

Medical Oncology: Subset Medical Oncology Faculty

Cancer Center, Yale: Thoracic Oncology Program

Yale Medical Group

Office of Cooperative Research

Board Certifications

  • Medical Oncology AB of Internal Medicine (1997)

  • Hematology (Internal Medicine) AB of Internal Medicine (1998)

Clinical Trials

Conditions Study Title
Lung Phase 3 - Nivo, or Nivo+Ipilmumab vs. platinum doublet chemo in chemotherapy-naive stage 4 or NSCLC
Lung Phase 3 study of MEDI4376+Tremelimumab or MEDI4376 Monoherapy vs. SoC Platinum Based Chemo in NSCLC
Lung Phase 2 Study of MPDL3280A Combined With CDX-1401 in NY-ESO 1 (+) IIIB, IV or Recurrent NSCLC
Lung CheckMate 331: CHECKpoint pathway and nivoluMAb clinical Trial Evaluation 331
Bladder, Lung, Other Digestive Organ, Other Urinary, Stomach, Phase I Ramucirumab + Pembro with Gastric or GEJ Adenocarcinoma, NSCLC or Tcell carcinoma of urothelium
Lung A randomized phase II trial of combination versus single agent chemotherapy in high-risk elderly pat
Lung S1403
Lung PINNACLE: Phase 1b/2 Study of Anti-Notch Antibody Therapy with Cisplatin and Etoposide in SCLC
Lung, Melanoma, skin Evaluating the Combination of MK-3475 and Sterotactic Body Radiotherapy in Patients With Metastatic
Lung, Phase I A Study of MPDL3280A in Combination With INCB024360 in Subjects With Previously Treated Stage IIIB o
Lung Safety and Efficacy of Abraxane Maintenance post Abraxane + Carboplatin in squamous cell lung cancer
Lung Biomarker-Driven Master Protocol for Squamous Cell Lung Cancer
Melanoma, skin PF-05082566 + MK-3475 IN ADVANCED SOLID TUMORS
Lung, Melanoma, skin Phase 2 Study of MK-3475 in Patients with Melanoma or NSCLC with Untreated Brain Mets
Colon, Kidney, Lung, Other Digestive Organ, Rectum, Stomach, Phase I Phase Ib Trial of MPDL3280A with Bev or with Bev + FOLFOX in Patients with Solid Tumors
Bladder, Breast - Female, Lung, Ovary, Pancreas, Stomach, Phase I Phase 1/2 Study of Nivolumab or Nivolumab with Ipilimumab for Advanced or Metastatic Solid Tumors
Lung Lung Cancer Mutation Consortium Protocol
Rectum, Soft Tissue, Stomach, Thyroid, Phase I, Bladder, Brain and Nervous System, Breast - Female, Cervix Uteri, Colon, Esophagus, Kidney, Larynx, Lip, Oral Cavity and Pharynx, Liver, Lung, Melanoma, skin, Multiple Myeloma, Non-Hodgkin's Lymphoma, Other Female Genital, Other Male Genital, Pancreas, Prostate PCD4989g: Phase I, Open-label MPDL3280A in solid tumors

Edit this profile

Contact Info

Rogerio C. Lilenbaum, MD
Patient Care Location
Smilow Cancer Hospital at Yale-New HavenSmilow Cancer Hospital at Yale - New Haven
35 Park Street, Ste North Pavilion 4

New Haven, CT 06511
View on map...
Mailing Address
20 York Street
New Haven, CT 06520-8021